BioCentury | Jan 30, 2012
Strategy

Committing to covalency

...not brought in a new small molecule drug discovery capability since 2000, when it bought Signal Pharmaceuticals Inc....
BioCentury | May 5, 2008
Strategy

Buying biology

...2006 Avidia Amgen (NASDAQ:AMGN) $380 Protein engineering 2005 Idun Pfizer (NYSE:PFE) $298 Apoptosis, caspases 2000 Signal Pharmaceuticals...
BioCentury | Jan 22, 2001
Tools & Techniques

Signal deal leads Celgene into SERMs

...at higher doses. CELG's work on SERMs, which is derived from its 2000 acquisition of Signal Pharmaceuticals Inc....
BioCentury | Jan 16, 2001
Company News

Acadia management update

...and Douglas Richards as VP of business development, formerly VP of business development at Signal Pharmaceuticals Inc. WIR...
BioCentury | Oct 23, 2000
Tools & Techniques

Antisense deal that keeps on giving

...in-house anti- tumor necrosis factor (TNF) program, and a program in signal transduction pathways with Signal Pharmaceuticals Inc....
BioCentury | Oct 23, 2000
Tools & Techniques

Serono tries BBG's new tack

...in-house anti- tumor necrosis factor (TNF) program, and a program in signal transduction pathways with Signal Pharmaceuticals Inc....
BioCentury | Sep 5, 2000
Company News

Celgene, Signal Pharmaceuticals deal

...on CELG's Thursday close of $74.75 (see BioCentury, July 3). Celgene Corp. (CELG), Warren, N.J. Signal Pharmaceuticals Inc....
BioCentury | Jul 3, 2000
Finance

2Q Financial Markets Review: A never-ending story

...than take on the risk of doing our own IPO." Last week. s takeout of Signal Pharmaceuticals Inc....
BioCentury | Jul 3, 2000
Strategy

Celgene's pathways play

...drug and for its roots in chiral drug development. Thus the company's decision to acquire Signal Pharmaceuticals Inc....
BioCentury | Jul 3, 2000
Company News

Celgene, Signal Pharmaceuticals deal

...shares, or $195 million (see BioCentury Extra, Friday June 30). Celgene Corp. (CELG), Warren, N.J. Signal Pharmaceuticals Inc....
Items per page:
1 - 10 of 41
BioCentury | Jan 30, 2012
Strategy

Committing to covalency

...not brought in a new small molecule drug discovery capability since 2000, when it bought Signal Pharmaceuticals Inc....
BioCentury | May 5, 2008
Strategy

Buying biology

...2006 Avidia Amgen (NASDAQ:AMGN) $380 Protein engineering 2005 Idun Pfizer (NYSE:PFE) $298 Apoptosis, caspases 2000 Signal Pharmaceuticals...
BioCentury | Jan 22, 2001
Tools & Techniques

Signal deal leads Celgene into SERMs

...at higher doses. CELG's work on SERMs, which is derived from its 2000 acquisition of Signal Pharmaceuticals Inc....
BioCentury | Jan 16, 2001
Company News

Acadia management update

...and Douglas Richards as VP of business development, formerly VP of business development at Signal Pharmaceuticals Inc. WIR...
BioCentury | Oct 23, 2000
Tools & Techniques

Antisense deal that keeps on giving

...in-house anti- tumor necrosis factor (TNF) program, and a program in signal transduction pathways with Signal Pharmaceuticals Inc....
BioCentury | Oct 23, 2000
Tools & Techniques

Serono tries BBG's new tack

...in-house anti- tumor necrosis factor (TNF) program, and a program in signal transduction pathways with Signal Pharmaceuticals Inc....
BioCentury | Sep 5, 2000
Company News

Celgene, Signal Pharmaceuticals deal

...on CELG's Thursday close of $74.75 (see BioCentury, July 3). Celgene Corp. (CELG), Warren, N.J. Signal Pharmaceuticals Inc....
BioCentury | Jul 3, 2000
Finance

2Q Financial Markets Review: A never-ending story

...than take on the risk of doing our own IPO." Last week. s takeout of Signal Pharmaceuticals Inc....
BioCentury | Jul 3, 2000
Strategy

Celgene's pathways play

...drug and for its roots in chiral drug development. Thus the company's decision to acquire Signal Pharmaceuticals Inc....
BioCentury | Jul 3, 2000
Company News

Celgene, Signal Pharmaceuticals deal

...shares, or $195 million (see BioCentury Extra, Friday June 30). Celgene Corp. (CELG), Warren, N.J. Signal Pharmaceuticals Inc....
Items per page:
1 - 10 of 41